Literature DB >> 2095855

Present state and future development of the therapy of Alzheimer disease.

M Pomponi1, E Giacobini, M Brufani.   

Abstract

Entities:  

Mesh：

Substances：

Year:  1990        PMID： 2095855     DOI： 10.1007/bf03323906

Source DB:  PubMed          Journal:  Aging (Milano)        ISSN： 0394-9532


× No keyword cloud information.
  4 in total

Review 1.  Differential diagnosis of dementia, delirium and depression. Implications for drug therapy.

Authors:  J Johnson; R Sims; G Gottlieb
Journal:  Drugs Aging       Date:  1994-12       Impact factor: 3.923

2.  Some blood biochemistry parameters during the cholinergic treatment of Alzheimer's disease.

Authors:  F I Braginskaya; M Zorina; N P Pal'mina; V D Gaintseva; E B Burlakova; N D Selezneva; I V Kolykhalov; S I Gavrilova
Journal:  Neurosci Behav Physiol       Date:  2001 Jul-Aug

3.  Phenserine: a physostigmine derivative that is a long-acting inhibitor of cholinesterase and demonstrates a wide dose range for attenuating a scopolamine-induced learning impairment of rats in a 14-unit T-maze.

Authors:  S Iijima; N H Greig; P Garofalo; E L Spangler; B Heller; A Brossi; D K Ingram
Journal:  Psychopharmacology (Berl)       Date:  1993       Impact factor: 4.530

4.  Preferential inhibition of acetylcholinesterase molecular forms in rat brain.

Authors:  N Ogane; E Giacobini; E Messamore
Journal:  Neurochem Res       Date:  1992-05       Impact factor: 3.996
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.